Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Hiroshi_Nomura
|
| gptkbp:country |
gptkb:Japan
|
| gptkbp:focusArea |
infectious diseases
neurology oncology psychiatry regenerative medicine |
| gptkbp:formerName |
gptkb:Dainippon_Sumitomo_Pharma
|
| gptkbp:founded |
1897
|
| gptkbp:headquarters_location |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sumitomo Pharma
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:ISIN |
JP3495000006
|
| gptkbp:member |
gptkb:Sumitomo_Group
|
| gptkbp:notableProduct |
gptkb:Aptiom
gptkb:Latuda gptkb:Lunesta gptkb:Cymbalta |
| gptkbp:numberOfEmployees |
about 7,000
|
| gptkbp:officialWebsite |
https://www.sumitomo-pharma.com/
|
| gptkbp:parentOrganization |
gptkb:Sumitomo_Group
|
| gptkbp:products |
pharmaceutical drugs
|
| gptkbp:revenue |
over 500 billion yen (recent years)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stockSymbol |
4506
|
| gptkbp:subsidiary |
gptkb:Sumitomo_Pharma_America
gptkb:Sumitovant_Biopharma |
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|